As previously reported, BofA analyst Alec Stranahan initiated coverage of Day One Biopharmaceuticals with a Buy rating and $34 price target, arguing that its lead candidate, tovorafenib, presents a better option than the current standard of care in pLGG and calling it "potentially a game-changer."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
- Day One Biopharmaceuticals reports Q3 EPS (53c), consensus (53c)
- Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
- Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
